Spectrum seeks rapid approval for anticancer contender


Spectrum Pharmaceuticals ($SPPI) hit the main efficacy goal of a midstage study of its drug belinostat for treating patients with certain cases of peripheral T-Cell lymphoma. And the company plans to advance the program, which has fast-track status in the U.S., to an FDA review next year. Article